Tempus AI

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

Tempus AI
Jan 15, 2025, 03:43 | Insight
Tempus AI Introduced xH: Its First Whole-Genome Sequencing Test
Tempus AI, Inc. a leader in integrating AI to enhance precision medicine and patient care,…
Oct 11, 2024, 16:38 | Blog
Sanjay Juneja: Leveraging AI to address Care Gaps and predict outcomes in Oncology
Sanjay Juneja, Co-Founder & President of Business Development, MedFluencers, shared a post on LinkedIn: "You…
Jul 29, 2024, 09:27 | Career
Ezequiel Renzulli: I am excited to announce the launch of Rio Sur Advisory Partners
Ezequiel Renzulli, Chief Executive Officer at Rio Sur Advisory Partners, shared on LinkedIn: "After six…
Jul 21, 2024, 12:32 | Blog
CancerX Moonshot's updated Solutions Catalog
CancerX Moonshot shared a post on LinkedIn: "We’ve updated our Solutions Catalog!     . The…
Jun 8, 2024, 11:24 | Blog
Kristiyana Kaneva: Packed several days at ASCO with Tempus AI
Kristiyana Kaneva, Executive Medical Director, Clinical Development at Tempus AI, shared a post on LinkedIn:…
May 1, 2024, 06:04 | Insight
Martin Stumpe: Predicting MSI in prostate cancer from hematoxylin and eosin stained biopsy
Martin Stumpe, Chief of AI at Tempus, shared on LinkedIn: “We recently published a paper…
Dec 13, 2023, 17:53 | Blog
Earle Burgess: Why don’t all advanced prostate cancer patients with pathogenic HRR gene mutations respond to parp inhibitors?
Earle Burgess, Chief of Genitourinary Oncology Section at Atrium Health, Levine Cancer Institute, shared a…
All: 7 Posts: 1 - 100
Special Coverage